The aim of this research is to investigate the mechanism and kinetics of drug release from the core and coated pellets containing sodium diclofenac. Avicel was found to be a good excipient to prepare matrix-type pellets. The drug release could be sustained up to 12 hours. the rate of drug release was fit to Higuchi's model. The microphotograph revealed that the drug release was controlled by the diffusion from the isoluble matrix. The drug release was sustained up to 24 hours. The rate of drug release was fit to Higuchi's model, too. The mechanism of drug release was determined to be the diffusion from insoluble matrix and through the insoluble membrane.
Diclofenac ; Pharmacokinetics

The in vitro correlation of sustained release sodium diclofenac 100mg capsule was characterized. Correlation at level A was established between the rate of in vitro release and that of in vivo absorption. Correlation coefficient was found at 0.9705. This correlation coefficient was found at dissolution test used in this research could be applied for quality control of the capsule. The results of the research also showed that the absorption in vivo was suitable for once-a-day dosage form.
Diclofenac ; Methods

In vitro, the release of sodium diclofenac from different ointment bases at 1% concentration was studied. The rank order of the release pass dialysis membrane was as follow: Emugel carbopol 934, CMC, HPMC gel> emulsified ointment> absorption ointment> hydrophobic ointment.
Diclofenac ; Ointments

The effect of the bases and added substances on the release and absorption of sodium diclofenac from its different ointment formulations was studied. The results shown that the released extent of sodium diclofenac from different ointment bases across dialysis membrane was following the order: water soluble bases > emulsion bases > emugel bases > hydrocarbon bases and carbopol 934 gel with 1.2% I-menthol > carbopol 934 gel with 0.5% I-menthol > carbopol 934 gel with 3% oleic acid > carbopol 934 gel only. The percutaneous absorbed extent of sodium diclofenac across the rat hairless skin was evaluated indirectly based on antiinflammatory action on the rat leg stimulated edema by 0.1 ml of 1% caragenin solution. The average reduced percent of leg edema volume of the experimented rat group was obtained in such order: carbopol 934 gel with 1.2% I-menthol > carbopol 934 gel with 0.5% I-menthol > carbopol 934 gel with 3% oleic acid > carbopol 934 gel only. This result demonstrated that there was a correlation between in vitro release and in vivo percutaneous absorption of sodium diclofenac through the rat hairless skin.
Diclofenac ; Ointments

A dormulation of pellet containing sodium diclofenac was carried out using Avicel, lactose as excipients. The obtained pellets were coated with EC to prolong the drug release. A diclofenac sustained release capsule was prepared by filling coated pellets into the capsule shell.
Diclofenac ; Pharmaceutical Preparations

Establishing the formulation of 0.1% diclofenac eye drops by making up solution and quantitative by High- Performance Liquid Chromatography (HPLC). Results: Natri diclofenac eye drop 0.1% mixing with phosphate buffer 0.05M get the most stability at pH=7.5. The percentage of propylene glycol and natrimetabisulfit in the formulation influenced significantly the stability of eye drop solution. The stability increased gradually if the rates of natri metabisulfit antioxygen are 0.1%; 0.2% and 0.3% or there was an increase of propylene glycol with the rate of 0%, 5% and 10%. This preparation is stable at least 5 months at temperature 50oC and protected from light. This preparation may be stable more than 20 months at room conditions 30oC and protected from light
Ophthalmic Solutions ; Diclofenac

Using the full quadratic model in drug dissolution optimization, the authors built up the sustained release of diclofenac tablet formulation with hydrophilic matrix excipient. The sustained excipient releases xanthan gum which has good features such as controlling medical substance regularly, rubbing seed easily, covering tablet easily and compressed force with a little affect to the rate of medical substance release. This formulation can be applied in making up medicines with a wider scale. It is being tested its stability and evaluated its availability to apply in manufacture
Diclofenac, Pharmaceutical Preparations , Tablets

Objective: The study determined the safety, efficacy and acceptability of a Philippine community preparation of Siling Labuyo liniment in the management of knee osteoarthritis. Methods: A 6-week randomized, double-blind, active-controlled clinical trial was conducted in three municipalities of Cavite from 2017-2018. The municipalities were randomly assigned to either the control or experimental group, using a commercially available Diclofenac 1% gel as the control agent. Knee Injury and Osteoarthritis Outcome Score (KOOS) and Pain Visual Analogue Scale (VAS) were used to measure the outcomes. Results: Forty-seven participants completed the study. Statistically significant improvement (p<0.05) in pain relief, reduction of symptoms and increase in knee functionality was reported by participants in both the experimental and control groups. Across the dimensions measured, at least 30% improvement in scores was reported by the experimental group, and at least 40% by the control group. The difference was statistically not significant (p>0.05). Itching (13%), burning sensation (11%) and reddening of the skin (15%) were experienced in both the experimental and the active control groups. Conclusion Use of the liniment led to a modest therapeutic effect and was well-tolerated by the participants.
Diclofenac ; Osteoarthritis, Knee ; Pain

A total of 80 cases undergone the routine phacoemulsification and the posterior chamber lens implantation under various topical anesthetics have been studied. The patients were divided into four groups from A to D and administered as follows : 4% lidocaine for 20 patients in group A, 4% lidocaine plus 0.5% proparacaine for 20 patients in group B, 0.1% diclofenac sodium plus 4% lidocaine for 20 patients in group C, 0.1% diclofenac sodium plus 0.5% proparacaine for 20 patients in group D. They were instilled into conjunctival sac at 20 minutes, 15 minutes, 10 minutes, 5 minutes and just before surgery. We also measured corneal thickness preoperatively, immediately after the operation, postoperative one week and observed corneal status during the operation and the pain score during surgery using a visual analogue scale. There was no statistical difference of corneal thickness among the groups. The pain score during surgery did not show any statistical significance. The topical anesthetics is a safe and convenient method for cataract surgery.
Anesthetics* ; Cataract ; Diclofenac ; Humans ; Lidocaine ; Phacoemulsification*

BACKGROUND: Soluble epoxide hydrolase (sEH) is an enzyme that converts epoxyeicosatrienoic acid (EET) into the anti-inflammatory dihydroxyeicosatrienoic acids (DHET). Inhibition of sEH by the potent soluble epoxide hydrolase inhibitor (sEHI) decreases inflammation by increasing EET. The K/BxN serum transfer mouse model of arthritis displays an initial inflammation and an associated tactile allodynia that continues on following the resolution of inflammation. METHODS: We undertook the following studies: i) Using the K/BxN mouse model, we examined effects on allodynia during the early inflammatory phase of administration of sEHI 3 mg/kg and/or diclofenac (DFC) 10 mg/kg. ii) In the late inflammatory phase, we administered sEHI (3, 10, or 30 mg/kg); DFC 10 mg/kg; gabapentin 100 mg/kg. iii) Using the conditioned place preference (CPP) we examined the synergism between sEHI and DFC in the K/BxN mouse using the CPP paradigm. The drug was administered intraperitoneally and the allodynia was measured with the von Frey test. RESULTS: In the early phase, both sEHI and DFC displayed an antiallodynic action. In the late phase, sEHI, and gabapentin but not DFC were effective in reversing the allodynia. Comparable results were observed with the CPP. CONCLUSIONS: This study demonstrates that sEHI reduces mechanical allodynia in both the early and the late inflammatory K/BxN mouse model of arthritis. The sEHI target thus addresses the hyperalgesia arising from inflammation as well as the post-inflammatory phase that has been said to reflect neuropathic-like states, thus presenting alternatives to the limited efficacy of arthritis drugs in use.
Animals ; Arthritis* ; Diclofenac ; Hyperalgesia ; Inflammation ; Mice*